Literature DB >> 2479733

HIV-1 reverse transcriptase/ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction.

R T D'Aquila1, W C Summers.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT)/ribonuclease H has been expressed to high levels in Escherichia coli from a recombinant plasmid constructed using the polymerase chain reaction (PCR) for in vitro mutagenesis. Translational initiation and termination codons were introduced by the PCR at points corresponding to sites of cleavage of the RT from the gag-pol precursor polyprotein by the HIV-1 protease; the HIV-1 protease is not expressed from this construct. Most of the RT coding sequences derived from PCR were exchanged for a DNA fragment cloned by standard methods to minimize the possibility that an unwanted mutation was introduced during the in vitro amplification. The RT is expressed in bacteria from this plasmid as 66 and 51 kDa proteins, has both RNA-dependent DNA polymerase and ribonuclease H (RNase H) activities, and is indistinguishable from native HIV-1 RT in electrophoretic mobility and immunoreactivity. Peptide sequencing of the amino terminus of the HIV-1 RT purified from bacterial lysates is also presented. A novel activity gel assay was used to confirm that only the 66 kd protein catalyzes the RNase H reaction; this assay will simplify analysis of this catalytic activity. This HIV-1 RT expression plasmid is of interest because of the high level of expression in bacteria and the demonstrated RNase H activity of the enzyme. This plasmid will be distributed for research purposes through the NIH AIDS Repository and will facilitate enzymologic, structural, and immunologic evaluation of reverse transcription and its chemotherapeutic inhibition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2479733

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  16 in total

1.  Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

Authors:  H Pelemans; R Esnouf; A Dunkler; M A Parniak; A M Vandamme; A Karlsson; E De Clercq; J P Kleim; J Balzarini
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Stable complexes formed by HIV-1 reverse transcriptase at distinct positions on the primer-template controlled by binding deoxynucleoside triphosphates or foscarnet.

Authors:  Peter R Meyer; Wiriya Rutvisuttinunt; Suzanne E Matsuura; Antero G So; Walter A Scott
Journal:  J Mol Biol       Date:  2007-03-12       Impact factor: 5.469

3.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.

Authors:  Antonio J Acosta-Hoyos; Suzanne E Matsuura; Peter R Meyer; Walter A Scott
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors.

Authors:  C K Shih; J M Rose; G L Hansen; J C Wu; A Bacolla; J A Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.

Authors:  R Pauwels; K Andries; Z Debyser; P Van Daele; D Schols; P Stoffels; K De Vreese; R Woestenborghs; A M Vandamme; C G Janssen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

8.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Reverse transcriptase of human immunodeficiency virus can use either human tRNA(3Lys) or Escherichia coli tRNA(2Gln) as a primer in an in vitro primer-utilization assay.

Authors:  L A Kohlstaedt; T A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor.

Authors:  J Jaeger; T Restle; T A Steitz
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.